Jamaica’s National Health Fund (NHF) has rolled out a sweeping set of enhancements to its cardiovascular care support network, marking one of the most significant updates to its heart health coverage in recent years. The core of this new policy sees the agency boost subsidies for 18 separate cardiovascular drug products, with per-unit increases landing between $40 and upwards of $200 for individual tablets and capsules.
In an official press statement, the NHF clarified that these immediate adjustments deliver direct financial relief to thousands of patients who rely on daily prescriptions for critical heart medications. This includes life-saving cholesterol-lowering and lipid-regulating treatments, as well as long-term therapies for ischaemic heart disease and chronic hypertension.
This latest round of subsidy increases builds on a series of targeted updates the NHF has rolled out since the start of the calendar year. Earlier in 2026, the agency added 11 new branded drug formulations to its covered list, and enacted an average subsidy hike of 10 to 20 percent for 207 distinct hypertension medication products. After these adjustments, the NHF notes that average subsidies now cover approximately half of the total retail cost of hypertension drugs, a change designed directly to offset the impact of widespread drug price inflation for program beneficiaries. The targeted focus on hypertension is no accident: the condition remains the most prevalent chronic illness enrolled in the NHFCard program, and is widely recognized as the top modifiable risk factor for life-threatening cardiovascular disease across Jamaica.
In a separate expansion that took effect in March 2026, the NHF added heart failure to the official list of covered conditions under the NHFCard program, bringing more than 253 additional heart failure medication products onto the subsidized roster. Alongside expanded drug coverage, the agency introduced two new key diagnostic benefits to improve early detection and ongoing monitoring of heart conditions. Eligible beneficiaries now qualify for an annual subsidy of $7,500 to cover the cost of an echocardiogram, and an additional $1,750 annual subsidy for electrocardiogram (ECG) testing. These additions reinforce the NHF’s long-stated commitment to expanding access to early intervention for cardiovascular disease, while cutting out-of-pocket costs that often force patients to delay necessary care.
“Cardiovascular disease remains one of the most pressing primary health challenges facing Jamaican families today, and addressing it effectively requires an intentional, focused approach,” said NHF Chief Executive Officer Everton Anderson. “Our core mandate has always centered on tearing down the financial barriers that block access to critical care. By continuously reviewing our program frameworks and reallocating resources to prioritize heart health and chronic disease support, we ensure the NHF evolves to meet the real, everyday needs of our population, delivering sustainable, long-term relief where it is needed most.”
This expanded investment in cardiac care is part of a broader, multi-year initiative by the NHF to scale up support for all chronic illnesses across Jamaica. Earlier this year, the agency expanded its list of covered chronic conditions from an earlier 22 to 28, adding new subsidized treatments for respiratory illnesses, gastrointestinal conditions, and multiple types of cancer. All of these updated subsidies are available immediately to active NHFCard beneficiaries at any participating private pharmacy location across the country.
Members of the public seeking additional details about the NHFCard program, or a full, updated list of covered chronic conditions and subsidized medications, can visit the official NHF website at www.nhf.org.jm, or reach the agency’s customer care team directly by phone at (876) 906-1106.